Mesoblast Ltd. (NASDAQ: MESO) Starts Presentation at 29th Annual Roth Conference
Mesoblast (NASDAQ: MESO) develops cell-based medicines. The company has leveraged its proprietary technology platform based on specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopaedic disorders, and oncologic/hematologic conditions. Mesoblast’s lead product candidates include MPC-150-IM, a phase 3 product candidate under investigation for the treatment of chronic congestive heart failure; and MPC-06-ID, a phase 3 product candidate under investigation for the treatment of chronic low back pain due…







